[Edaily Reporter Kwon Oh Seok ] ITEYES Inc.(372800)’s stock price surged to the daily upper limit early in the trading session. It appears that buying interest is surging following news that the company is set to target the next-generation bio and healthcare AI market.

According to MP Doctor on the 2nd, as of 9:16 a.m., ITEYES Inc. is trading at 2,780 won—the daily price limit—up 29.91% from the previous trading day.
Earlier that day, ITEYES Inc. issued a press release announcing that it had signed a Memorandum of Understanding (MOU) with Vaxcell-Bio Therapeutics to collaborate on AI-based new drug development.
The core of this agreement is to jointly drive AI innovation across the entire new drug development lifecycle by combining ITEYES Inc.’s “GENAI ME”-based medical AI platform technology with Vaxcell-Bio Therapeutics’ capabilities in developing cell and gene therapies (CGT) and anti-cancer immunotherapies.
Through this agreement, the two companies have agreed to collaborate closely in key areas of new drug development, including △AI-based candidate compound discovery △optimization of gene delivery vectors △streamlining of manufacturing processes △design of patient-tailored therapies △AI-based clinical trial design △and development of patient cohort prediction models. Additionally, they plan to actively utilize ITEYES Inc.’s AI solutions in the new biotech ventures being pursued by Vaxcell-Bio Therapeutics to jointly explore new business models.